PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.

about

PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients.

Item

http://www.wikidata.org/entity/Q49996562

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@en

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@nl

type

Item

label

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@en

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@nl

prefLabel

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@en

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@nl

P1476

PIK3CA and TP53 mutations pred ...... II colorectal cancer patients.

@en

P2093

A-Jian Li

http://www.w3.org/2001/XMLSchema#string

Er-Jiang Tang

http://www.w3.org/2001/XMLSchema#string

Hua-Guang Li

http://www.w3.org/2001/XMLSchema#string

Hui-Hong Jiang

http://www.w3.org/2001/XMLSchema#string

Lu Yin

http://www.w3.org/2001/XMLSchema#string

Mou-Bin Lin

http://www.w3.org/2001/XMLSchema#string

Wei Wu

http://www.w3.org/2001/XMLSchema#string

Ying Chen

http://www.w3.org/2001/XMLSchema#string

P2860

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

High frequency of mutations of the PIK3CA gene in human cancers

5-fluorouracil: mechanisms of action and clinical strategies

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Oncogenic mutations of PIK3CA in human cancers

P304

631-640

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V24.I5.631

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29434452

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5799864

http://www.w3.org/2001/XMLSchema#string